Arcus Biosciences, Inc. (RCUS) Earnings Signals & AI Vibe Check
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Arcus Biosciences, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Arcus Biosciences, Inc.'s filing signal
continuing negative.
earningsVibe SuperAnalyst™ Verdict:
CONTINUING NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
+0.05%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Arcus Biosciences, Inc. actually do?
Answer:
Arcus Biosciences is a late clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies for cancer and inflammatory/autoimmune diseases. The company's lead oncology asset, casdatifan, a HIF-2α inhibitor, is in Phase 3 registrational studies for renal cell carcinoma, with potential peak sales exceeding $5 billion across two indications. Arcus is also advancing quemliclustat, a CD73 inhibitor, in a Phase 3 trial for pancreatic cancer, and domvanalimab, an anti-TIGIT antibody, in Phase 3 trials for non-small cell lung cancer. Its inflammation pipeline includes an MRGPRX2 antagonist program targeting chronic spontaneous urticaria and atopic dermatitis. Arcus leverages internal discovery capabilities and strategic collaborations, notably with Gilead Sciences, to advance its differentiated pipeline.
Question:
What are Arcus Biosciences, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by license and development services fees, milestone payments, and royalties from strategic collaborations, notably with Gilead Sciences and Taiho Pharmaceutical Co., Ltd.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required